EGFR and neoplasm: TP53 mutations disrupt the tumor-suppressive function of the p53 protein and are associated with poorer objective response rates, shorter progression-free survival, and reduced overall survival when treated with ALK-TKIs or EGFR-TKIs (29, 30).